| Identification | Back Directory | [Name]
Apararenone | [CAS]
945966-46-1 | [Synonyms]
MT-3995
Apararenone
Apararenone/MT-3995
inhibit,Inhibitor,Mineralocorticoid Receptor,MT 3995,Apararenone,MT3995
Methanesulfonamide, N-[4-(4-fluorophenyl)-3,4-dihydro-2,2-dimethyl-3-oxo-2H-1,4-benzoxazin-7-yl]-
N-(4-(4-Fluorophenyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)methanesulfonamide | [Molecular Formula]
C17H17FN2O4S | [MOL File]
945966-46-1.mol | [Molecular Weight]
364.39 |
| Chemical Properties | Back Directory | [Boiling point ]
594.3±60.0 °C(Predicted) | [density ]
1.389±0.06 g/cm3(Predicted) | [solubility ]
DMSO: Sparingly soluble: 1-10 mg/ml | [form ]
Solid | [pka]
8.02±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. | [in vivo]
Recently, a phase II clinical trial has been initiated among patients with non-alcoholic steatohepatitis (NASH) in Japan[1]. | [References]
[1] Kolkhof P, et al. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017 Jul;234(1):T125-T140. DOI:10.1530/JOE-16-0600 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|